AstraZeneca has agreed to sell some of the rights to its drugs Nexium and Vimovo to Grünenthal for an upfront payment of $922 million. The move represents the biggest single investment to date ...

Pfizer has announced a deal with AstraZeneca for exclusive over-the-counter (OTC) rights to market Nexium for approved indications in the United States, Europe and the rest of the world.